Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Surv Ophthalmol. 2017 Dec 27;63(4):453–479. doi: 10.1016/j.survophthal.2017.12.008

Figure 8. Fate of high-risk MHC-disparate corneal transplants in mice (n= 14/group) after anti-CD154 treatment was discontinued at week 8 after transplantation.

Figure 8

Graft rejection was scored clinically (A), and graft survival data are presented as Kaplan–Meier survival curves (B). Only one rejection occurred after cessation of anti-CD154 therapy (**P = 0.0002).155 (Adapted from Qain et al with permission from IOVS)